Policy Board of the Drug Regulatory Authority of Pakistan (DRAP) has given policy guidelines for inspections of manufacturers keeping in view the suggestions/guidelines of WHO for reliance on other regulatory authorities. Accordingly, the revised “Policy for inspections of manufacturers abroad” as approved by the Policy Board under Section 11 (I) (a) of the DRAP Act, 2012, as under:-
- DRAP notified National Pharmacovigilance Centre (NPC) under the Pharmacovigilance Rules, 2022
- Draft amendments in rules framed under Drug Act 1976 (for comments within 7 days of publication of SRO).